



Ron H J Mathijssen

Contact

Ron H J Mathijssen

Publications (12)

Hertz D, Jörger M, Bang Y, Mathijssen R, Zhou C, Zhang L, Gandara D, Stahl M, Monk B, Jaehde U, Beumer J. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. *Eur J Cancer* 2024; 202:114024.

de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, Läubli H, Michielin O, von Moos R, Jörger M, Levesque M, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex S, Mathijssen R, Metaxas Y. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. *J Immunother* 2024; 47:190-194.

Agema B, Buck S, Viskil M, Isebia K, de Neijls M, Sassen S, Koch B, Jörger M, de Wit R, Koolen S, Mathijssen R. Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia. *Eur Urol Oncol* 2023

Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaour I, Larcher-Senn J, Buck S, Mathijssen R, Jaehde U, Gillessen S, Jörger M. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* 2023; 29:1887-1893.

Groenland S, Verheijen R, Jörger M, Mathijssen R, Sparreboom A, Beijnen J, Beumer J, Steeghs N, Huitema A. Precision Dosing of Targeted Therapies Is Ready for Prime Time. *Clin Cancer Res* 2021; 27:6644-6652.

Hurkmans D, Mathijssen R, Aerts J, van der Veldt A, Schreurs M, van der Leest C, Koch B, Debets R, Jörger M, Wijkhuijs A, Basak E, Putter L, de Joode K, Sassen S, Koolen S. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. *J Immunother Cancer* 2021; 9

Mueller-Schoell A, Schwab M, Zgheib N, Tfayli A, Chowbay B, Chen S, Eccles D, Copson E, Mathijssen R, Koolen S, Neven P, Jörger M, Huisinga W, Brauch H, Michelet R, Mürdter T, Schroth W, Klopp-Schulze L, Kloft C. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. *Clin Pharmacol Ther* 2020; 108:661-670.

Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen S, Mathijssen R, Jörger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. *Front Pharmacol* 2020; 11:283.

Crombag M, Koolen S, Wijngaard S, Jörger M, Dorlo T, van Erp N, Mathijssen R, Beijnen J, Huitema A. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. *Pharm Res* 2019; 36:163.

Hurkmans D, Mathijssen R, Aerts J, van der Leest C, van der Veldt A, Odink A, Jörger M, Debets R, Hoop E, Bins S, Wijkhuijs A, Schreurs M, Mercieca D, van Dijk T, Basak E, Koolen S. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. *J Immunother Cancer* 2019; 7:192.

Crombag M, Beijnen J, Mathijssen R, van Erp N, Dorlo T, Schellens J, Jörger M, Wijngaard S, Koolen S, de Vries Schultink A, Huitema A. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. *Pharm Res* 2019; 36:33.

Kraff S, Nieuweboer A, Mathijssen R, Baty F, de Graan A, van Schaik R, Jaehde U, Jörger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. *Cancer Chemother Pharmacol* 2015

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch